Heart failure

@article{Metra2017HeartF,
  title={Heart failure},
  author={Marco Metra and John R. Teerlink},
  journal={The Lancet},
  year={2017},
  volume={390},
  pages={1981-1995}
}
Heart failure is common in adults, accounting for substantial morbidity and mortality worldwide. Its prevalence is increasing because of ageing of the population and improved treatment of acute cardiovascular events, despite the efficacy of many therapies for patients with heart failure with reduced ejection fraction, such as angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), β blockers, and mineralocorticoid receptor antagonists, and advanced device therapies… Expand
New horizons in management of heart failure in older patients.
TLDR
The basic approach to manage heart failure patients with an ejection fraction of <40% should be the same in older and younger, and there is an urgent need for more research, evidence and resources directed towards older populations with heart failure to improve their care and the quality of life. Expand
The effects of antidiabetic agents on heart failure
TLDR
SGLT2 inhibitors have been shown to be benefit on top of recommended heart failure therapy including sacubitril/valsartan and may also prove beneficial for heart failure with preserved ejection fraction. Expand
Heart Failure With Preserved Ejection Fraction and Adipose Tissue: A Story of Two Tales
TLDR
This review discusses features of the obese-HFpEF phenotype and highlights proposed mechanisms implicated in the inter-tissue communication between adipose tissue and the heart in obesity-associated HFpEF. Expand
Neurological complications of heart failure.
  • A. Massaro
  • Medicine
  • Handbook of clinical neurology
  • 2021
TLDR
The steady improvement of neuroimaging techniques has demonstrated an increased prevalence of silent ischemic lesions among HF patients, and the populations most likely to benefit from long-term anticoagulant therapy are HF patients with AF. Expand
The management of worsening heart failure
TLDR
Biomarkers such as elevated levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) are increasingly used to evaluate global function as stretching of the myocardium due to the elevated intracardiac pressure is responsible for their elevation. Expand
New drugs for the treatment of chronic heart failure with a reduced ejection fraction: What the future may hold.
TLDR
New drugs recently introduced for HFrEF treatment need implementation in clinical practice, as well as further studies to possibly expand their indications. Expand
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF.
TLDR
The GALACTIC-HF trial is the first trial examining whether selectively increasing cardiac contractility in patients with HF with reduced ejection fraction will result in improved clinical outcomes and has 90% power to assess a final hazard ratio of approximately 0.80. Expand
The Heart Failure with Preserved Ejection Fraction Conundrum—Redefining the Problem and Finding Common Ground?
TLDR
HFpEF is likely to see new thinking in the coming decades after the last several years have seen guidelines changing to account for greater epidemiological observations. Expand
Heart failure with preserved ejection fraction: an update on pathophysiology, diagnosis, treatment, and prognosis
TLDR
The latest knowledge of HFpEF pathophysiology is updated, the existing promising diagnostic methods and treatments are introduced, and its prognosis is summarized by reviewing the most recent cohort studies. Expand
Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
TLDR
The rationale for using ARNIs is presented, the RCTs showing their efficacy, updated recommendations from recent guidelines, and practical points about ARNI initiation and up-titration are provided. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 450 REFERENCES
Prevention and management of chronic heart failure in management of asymptomatic patients.
TLDR
It is important to educate the entire medical community, particularly physicians in the primary care setting, about recognition and treatment of asymptomatic patients with systolic left ventricular (LV) dysfunction and the prevention of clinical manifestations of heart failure. Expand
Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade.
TLDR
Major therapeutic guidelines in the United States and Europe now strongly recommend that all eligible patients with concomitant heart failure post-AMI be treated with an aldosterone blocker in addition to an ACE inhibitor (or an ARB) and a beta-blocker. Expand
Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial
TLDR
This post hoc analysis demonstrated greater potassium and creatinine changes and possible clinical benefits with spironolactone in patients with heart failure and preserved ejection fraction from the Americas. Expand
Drugs for left ventricular remodeling in heart failure.
TLDR
Changes in LV dimensions rather than in ejection fraction should be used to monitor remodeling, and biventricular pacing is associated with functional improvement and reverse remodeling in patients with advanced HF and electromechanical dyssynchrony. Expand
Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients
TLDR
LVEF is a powerful predictor of cardiovascular outcome in heart failure patients across a broad spectrum of ventricular function, and once elevated to a range above 45%, ejection fraction does not further contribute to assessment of cardiovascular risk inheart failure patients. Expand
Statin therapy is associated with lower mortality among patients with severe heart failure.
TLDR
Although this observational study does not prove causality, further investigation of potential benefits of statins in patients with severe heart failure appears warranted. Expand
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
TLDR
Atrial fibrillation is associated with an increased risk of CV outcomes in patients with chronic heart failure and either reduced EF or PEF and Candesartan improved outcomes similarly regardless of baseline rhythm. Expand
Effect of statin therapy on survival in patients with nonischemic dilated cardiomyopathy (from the Beta-blocker Evaluation of Survival Trial [BEST]).
TLDR
In patients with moderate or severe HF due to non-IDC entered into BEST, statin therapy at entry was independently associated with a decrease in all-cause and cardiovascular mortality. Expand
New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.
TLDR
To maximize the likelihood of identifying effective therapeutics for HF-PEF, lessons learned from the past decade of research should be applied to the design, conduct, and interpretation of future trials. Expand
Heart failure with better ejection fraction: a modern diagnosis.
The emerging population of heart failure with improved ejection fraction, characterized in this issue of Circulation by Basuray et al1for 3 heart failure centers, testifies to the cumulative benefitExpand
...
1
2
3
4
5
...